Fig 5 - حسب Xiaoqing Chen (89898)

الموضوعات:

The global disease burden of osteoarthritis for both sexes in 204 countries and territories. حسب Xiaoqing Chen (89898)

الموضوعات:

Base-case analysis. حسب Akiko Kowada (14659965)

"…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …"

LPS administration demonstrated a significant decrease in the protein expression of both claudin-1 and occludin in BF fed mice as compared to control mice. حسب Valentina Di Caro (510473)

Bacterial groups that showed a significantly decreased abundance after antibiotic treatment (AMC and DOX group) compared to the control group (CON group). حسب Evangelia M. Stavroulaki (11840809)

Podocyte specific KO of FcRn results in a significant decrease in albuminuria, glomerulosclerosis, and glomerular crescents after nephrotoxic serum nephritis induction. حسب James F. Dylewski (9922380)

"…Podocyte-specific KO of FcRn results in a significant decrease in the number of crescents (p = 0.0007).…"

Podocyte specific KO of FcRn results in a significant decrease in glomerular crescents 8 days after anti-GBM disease induction. حسب James F. Dylewski (9922380)

"…Podocyte-specific KO of FcRn results in a significant decrease in the number of crescents (a, p = 0.035).…"

HPV16 E1 decreases cell growth. حسب Fern Baedyananda (11888703)

S4 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S1 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S5 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S3 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S6 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S2 Fig - حسب R. J. S. D. Heine (17889199)

الموضوعات:

S1 Data - حسب R. J. S. D. Heine (17889199)

الموضوعات:

CBP per cumulative year for daratumumab and pembrolizumab per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

CBP per cumulative indication for daratumumab and pembrolizumab per vial. حسب R. J. S. D. Heine (17889199)

الموضوعات:

Data set for study. حسب Aiman Aslam (15213610)

الموضوعات:

Summary of patient characteristics. حسب Aiman Aslam (15213610)

الموضوعات:

Genetic test outcome for all patients and family history breakdown for patients with negative genetic results. حسب Aiman Aslam (15213610)

الموضوعات: